A new study presented at SLEEP 2023 emphasized that, in addition to getting sufficient sleep each night, adults should maintain a consistent sleep schedule with a regular bedtime and wake time. Results show that adults with a regular sleep schedule and sufficient sleep duration had a 39% lower mortality risk than adults with an irregular…
Although the regulation of sleep—how much, when, and how sleep occurs—is mainly considered to be controlled by the brain, sleep deprivation also affects the body, and signals from the body can affect sleep. However, the ways in which the body regulates sleep are largely unknown. Now, Japanese researchers have revealed that sleep in worms is…
Date and Time June 22, 20233:00–4:00 p.m. ET Overview During this virtual fireside chat, Mary Woolley, president and CEO of Research!America, and National Institute of Mental Health (NIMH) Director Joshua A. Gordon, M.D., Ph.D., will discuss the importance of advocacy to ensure we have a strong and thriving health and medical research system. They will discuss…
What young men will be, in all probability, depends on what they are now. Young men seem to forget this. I am a pastor, and my occupational duty requires me to read. So for the past 35 years, I have acquired literally tons of books. My office, my house, and even my bedroom are all…
People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and emergency room visits as well as related costs by being adherent to positive airway pressure (PAP) therapy, according to two studies supported by ResMed and presented at SLEEP 2023. One retrospective study showed people with OSA and systolic heart failure and…
Harmony Biosciences Holdings Inc presented safety and efficacy data from a phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in people with Prader-Willi syndrome at SLEEP 2023. The positive signal supports further development to determine if pitolisant has the potential to address an unmet medical need for people with Prader-Willi…
Avadel Pharmaceuticals plc announced that Lumryz—an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy—is now commercially available. “We are proud to announce that Lumryz is commercially available through both our RYZUP patient support program and our specialty…
New data from the National Sleep Foundation’s (NSF) Sleep Health Index show a significant increase in the percentage of US adults who sleep less than the NSF-recommended seven to nine hours per night, as more restrictions were lifted during the COVID-19 pandemic. NSF’s findings showed a 40% increase in the percentage of US adults who…